Dormancy programs as emerging antimetastasis therapeutic alternatives

Area of Science:

• Oncology
• Molecular Biology
• Gene Regulation

Background:

• Residual tumor cells can remain dormant after surgery, posing a risk for future metastasis.
• The gene NR2F1 (nuclear receptor subfamily 2, group F, member 1) has been identified as a key regulator of tumor cell dormancy.

Purpose of the Study:

• To investigate the role of NR2F1 in mediating tumor cell dormancy.
• To explore therapeutic strategies for inducing tumor cell dormancy using NR2F1 reactivation.

Main Methods:

• Analysis of NR2F1 gene expression in residual tumor cells.
• Treatment of malignant cells with azacytidine and retinoids to assess NR2F1 pathway modulation.

Main Results:

• NR2F1 was confirmed to mediate the postsurgical dormancy of both local residual and disseminated tumor cells.
• The combination of azacytidine and retinoids effectively induced tumor cell dormancy by restoring the NR2F1-regulated gene program.

Conclusions:

• NR2F1 plays a critical role in maintaining tumor cell dormancy post-surgery.
• Targeting the NR2F1 pathway with azacytidine and retinoids presents a promising therapeutic approach to control minimal residual disease and prevent metastasis.